Calidi Biotherapeutics, Inc.
CLDI
$1.56
-$0.18-10.35%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.81% | -34.22% | -62.28% | -22.59% | 7.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.87% | -25.03% | -59.00% | -27.63% | -11.70% |
| Operating Income | 1.87% | 25.03% | 59.00% | 27.63% | 11.70% |
| Income Before Tax | 0.03% | 29.94% | 49.65% | -151.86% | 53.92% |
| Income Tax Expenses | -50.00% | -25.00% | 200.00% | -109.09% | 100.00% |
| Earnings from Continuing Operations | 0.10% | 29.94% | 49.59% | -150.44% | 53.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.90% | 30.99% | 50.21% | -149.70% | 53.87% |
| EBIT | 1.87% | 25.03% | 59.00% | 27.63% | 11.70% |
| EBITDA | 3.28% | 25.25% | 59.59% | 28.17% | 20.27% |
| EPS Basic | 10.10% | 90.94% | 88.39% | 54.33% | 94.60% |
| Normalized Basic EPS | 36.42% | 91.03% | 88.49% | 40.15% | 92.41% |
| EPS Diluted | 10.10% | 90.94% | 88.39% | 54.33% | 94.60% |
| Normalized Diluted EPS | 36.42% | 91.03% | 88.49% | 40.15% | 92.41% |
| Average Basic Shares Outstanding | 55.20% | 662.02% | 328.96% | 446.98% | 506.56% |
| Average Diluted Shares Outstanding | 55.20% | 662.02% | 328.96% | 446.98% | 506.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |